This is an automatically translated article.
Tazocin is a lyophilized antibiotic powder for intravenous infusion with the main ingredients being piperacillin and tazobactam. Tazocin 4.5g is indicated for the treatment of systemic and/or local infections caused by susceptible gram-positive and gram-negative aerobic and anaerobic bacteria.1. What is Tazocin?
Tazocin is a lyophilized powder for intravenous solution, each 4.5g vial of Tazocin contains piperacillin sodium equivalent to 4g piperacillin and tazobactam sodium equivalent to 0.5g tazobactam and 1 mg disodium edetat (dihydrate).
2. Indications of Tazocin 4.5g
Tazocin is indicated for the treatment of systemic and/or local infections caused by gram-positive and gram-negative anaerobic and gram-negative bacteria sensitive to piperacillin/tazobactam or piperacillin:
Adults:
Infections lower respiratory tract. Urinary tract infections. Intra-abdominal infection. Skin infections Bacteremia. Gynecological infections: pelvic inflammatory disease, endometritis from the puerperium Febrile infections with neutropenia. Musculoskeletal infections. Children (2 years and older):
Infection with fever with neutropenia. Intra-abdominal infection. In severe infections, empiric treatment with Tazocin may be initiated before the results of susceptibility testing are available.
3. Dosage and usage of Tazocin
Tazocin is given as a slow intravenous infusion over about 20-30 minutes.
Adults and children over 12 years: the total recommended daily dose is 12g piperacillin / 1.5g tazobactam, divided into divided doses, each 6 hours or 8 hours apart.
Neutropenia in children: combination therapy with aminoglycosides if fever is accompanied by neutropenia:
Children with normal renal function and weight less than 50kg, adjust dose to 80mg piperacillin/10mg tazobactam/kg body weight, 6 hours apart, in combination with an appropriate dose of aminoglycosides. Children weighing more than 50 kg, used according to the adult dose, in combination with aminoglycosides Intra-abdominal infections in children: For children from 2 to 12 years old, weighing < 40 kg, with normal renal function, the recommended dose 100 mg piperacillin/12.5 mg tazobactam/kg body weight, administered every 8 hours. For children from 2 to 12 years old, weighing > 40kg, with normal kidney function, use the adult dose. The recommended duration of treatment is a minimum of 5 days and a maximum of 14 days, and treatment should be continued for at least 48 hours after signs and symptoms have improved.
Elderly: The dose should be adjusted in the elderly with impaired renal function.
4. Contraindications of Tazocin
In cases of hypersensitivity to any beta-lactam (including penicillins and cephalosporins) or to beta-lactamase inhibitors.
5. Special warnings and precautions when using Tazocin
Before initiating treatment with Tazocin, a thorough investigation of previous hypersensitivity reactions to penicillins, cephalosporins and other allergens should be sought. Serious, sometimes fatal, hypersensitivity reactions have been reported in patients treated with penicillins. These reactions are more likely to occur in people with a history of hypersensitivity to multiple allergens.
Antibiotic-induced pseudomembranous colitis with signs and symptoms such as severe, life-threatening diarrhea. Symptoms of pseudomembranous colitis may develop during or after antibiotic therapy. Bleeding manifestations have occurred in some patients receiving beta-lactam antibiotics. These reactions are sometimes accompanied by abnormal results of coagulation tests such as clotting time, prothrombin time, platelet aggregation and are more likely to occur in patients with renal failure. Tazocin preparations containing sodium may increase the total sodium intake of the patient. Hypokalemia may occur in patients with reduced potassium stores or in those receiving concomitant medications that reduce potassium levels; Electrolyte levels should be checked periodically in these patients. As with treatment with other penicillins, convulsive neurologic complications may occur at high doses, particularly in patients with impaired renal function. The use of antibiotics can lead to overgrowth of non-susceptible microorganisms, including fungi, requiring close monitoring of the patient during treatment. If superinfection occurs, appropriate treatment should be instituted. Use in patients with renal impairment: In patients with renal impairment or in hemodialysis patients, the intravenous dose may be adjusted according to the degree of renal impairment. Effects on fertility, pregnancy and lactation: Animal studies have shown no teratogenic effects with the intravenous piperacillin-tazobactam combination, however toxicity has been reported. reproductive toxicity in rats at maternally toxic doses when administered intravenously or peritoneally. There are no adequate and well-controlled studies where the combined use of piperacillin-tazobactam or piperacillin or tazobactam has been toxic in pregnant women. Piperacillin and tazobactam cross the placenta. Therefore, the drug should be used during pregnancy only if the benefits outweigh the possible risks to the mother and fetus. Piperacillin is excreted in low concentrations in breast milk; Tazobactam concentrations in breast milk have not been studied. Breastfeeding women should take the drug only when the benefits outweigh the possible risks to the mother and the nursing infant.
6. Undesirable effects when taking Tazocin
Common: Candida infection, thrombocytopenia, anemia, insomnia, headache, diarrhea, abdominal pain, vomiting, constipation, nausea, dyspepsia, rash, itching, fever, injection site reaction , alanine aminotransferase increased, aspartate aminotransferase increased, total protein decreased, blood albumin decreased, positive Coombs test, blood creatinine increased, blood alkaline phosphatase increased, blood urea increased, activated partial thromboplastin time prolonged. Uncommon: Leukopenia, hypokalemia, hypotension, phlebitis, thrombophlebitis, hot flushes, erythema multiforme, urticaria, maculopapular rash, arthralgia, myalgia , chills, hypoglycemia, hyperbilirubinemia, prolonged prothrombin time. Tazocin is a lyophilized antibiotic powder for intravenous infusion with the main ingredients being piperacillin and tazobactam. Tazocin 4.5g is indicated for the treatment of systemic and/or local infections caused by susceptible gram-positive and gram-negative aerobic and anaerobic bacteria. To ensure the effectiveness of treatment and avoid unwanted side effects, patients need to strictly follow the instructions of the doctor, professional pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
